The benzodiazepine market is not merely crowded, but saturated, which is absurd. As a group the benzodiazepines are therapeutically important and commercially successful, so that it makes sense for manufacturers to compete for a slice of the cake. But ‘me-too’ and ‘me-again’ products confuse many prescribers, and harm patients who are switched from a drug that does not suit them to another which is almost indistinguishable. It is a serious shortcoming in the Medicines Act that the regulatory authority has no power to prevent the marketing of me-too products that offer no tangible advantages.1 Two new benzodiazepine preparations fall into this category.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.